Characteristics of oral mucosal events related to bevacizumab treatment

Oncologist

Volumn 17, Issue 2, 2012, Pages 274-278

  Gavrilovic, Igor T ^a   Balagula, Yevgeniy ^a   Rosen, Alyx C ^a   Ramaswamy, Vijay ^a   Dickler, Maura N ^a   Dunkel, Ira J ^a   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab mucosal toxicity adverse event geographic tongue

Indexed keywords

ACICLOVIR; BEVACIZUMAB; BISMUTH SALICYLATE; CARBOPLATIN; CARMUSTINE; CETIRIZINE; DIPHENHYDRAMINE; FLUCONAZOLE; LETROZOLE; MOUTHWASH; RANITIDINE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; BREAST CANCER; BURNING SENSATION; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EROSION; ERYTHEMA; FEMALE; GEOGRAPHIC TONGUE; GLIOBLASTOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKERATOSIS; MALE; MEAN CORPUSCULAR VOLUME; METASTASIS; MOUTH PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; THRUSH;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; RETROSPECTIVE STUDIES; TONGUE;

EID: 84857417613     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0198     Document Type: Review

References (22)

1. Cohen MH, Shen YL, Keegan P et al. FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. The Oncologist 2009;14:1131-1138.
2. Mukherji SK. Bevacizumab (Avastin). AJNR Am J Neuroradiol 2010;31:235-236.
3. FDA Approval for Bevacizumab. Available at http://www.cancer.gov/cancertopics/druginfo/fdabevacizumab. Accessed April 2011.
4. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-477.
5. Di Lorenzo G, Porta C, Bellmunt J et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59:526-540.
6. Prinz H. Wandering rash of the tongue (geographic tongue). Dent Cosmos 1927;69:272-275.
7. Bànóczy J, Szabó L, Csiba A. Migratory glossitis. A clinical-histologic review of seventy cases. Oral Surg Oral Med Oral Pathol 1975;39: 113-121.
8. Hume WJ. Geographic stomatitis: A critical review. J Dent 1975;3:25-43.
9. Drage LA, Rogers RS 3rd. Clinical assessment and outcome in 70 patients with complaints of burning or sore mouth symptoms. Mayo Clin Proc 1999;74:223-228.
10. Menni S, Boccardi D, Crosti C. Painful geographic tongue (benign migratory glossitis) in a child. J Eur Acad Dermatol Venereol 2004;18:737-738.
11. Abe M, Sogabe Y, Syuto T et al. Successful treatment with cyclosporin administration for persistent benign migratory glossitis. J Dermatol 2007; 34:340-343.
12. Reamy BV, Derby R, Bunt CW. Common tongue conditions in primary care. Am Fam Physician 2010;81:627-634.
13. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: A narrative literature review. Oral Oncol 2011;47:441-448.
14. Assimakopoulos D, Patrikakos G, Fotika C et al. Benign migratory glossitis or geographic tongue: An enigmatic oral lesion. Am J Med 2002; 113:751-755.
15. Yarom N, Cantony U, Gorsky M. Prevalence of fissured tongue, geographic tongue and median rhomboid glossitis among Israeli adults of different ethnic origins. Dermatology 2004;209:88-94.
16. Shulman JD, Carpenter WM. Prevalence and risk factors associated with geographic tongue among US adults. Oral Dis 2006;12:381-386.
17. Patki AH. Geographic tongue developing in a patient on lithium carbonate therapy. Int J Dermatol 1992;31:368-369.
18. Gracious BL, Llana M, Barton DD. Lithium and geographic tongue. J Am Acad Child Adolesc Psychiatry 1999;38:1069-1070.
19. Pammer J, Weninger W, Mildner M, et al. Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. J Pathol 1998;186:186-191.
20. Takahashi H, Sato M, Tsukada K, et al. [A retrospective study of oral adverse events with colorectal cancer chemotherapy using bevacizumab]. Gan To Kagaku Ryoho 2011;38:959-962.
21. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-3247.
22. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357: 2666-2676.